tradingkey.logo

Vaxart Reports Positive Clinical Data Demonstrating Second-Generation Vaccine Technology Produces Stronger Antibody Responses Than First-Generation

ReutersJun 11, 2025 11:47 AM

- Vaxart Inc VXRT.O:

  • VAXART REPORTS POSITIVE CLINICAL DATA DEMONSTRATING THAT ITS SECOND-GENERATION VACCINE TECHNOLOGY PRODUCES MUCH STRONGER ANTIBODY RESPONSES THAN ITS FIRST-GENERATION TECHNOLOGY

  • VAXART INC: VACCINE CANDIDATES WERE SAFE AND WELL-TOLERATED ACROSS ALL DOSE GROUPS WITH NO VACCINE-RELATED SERIOUS ADVERSE EVENTS REPORTED

  • VAXART INC - VACCINE CANDIDATES SAFE AND WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS

  • VAXART INC - PHASE 3 TRIAL COULD BEGIN AS EARLY AS 2026

  • VAXART: SECOND-GENERATION NOROVIRUS CONSTRUCTS PRODUCE STATISTICALLY SIGNIFICANT RISES IN GI.1 & GII.4 BLOCKING ANTIBODIES VERSUS FIRST-GENERATION

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI